HROW stock news · Harrow, Inc.

Stories about Harrow, Inc. (HROW) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for HROW

Follow Harrow, Inc. (HROW) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 5, 2026, 7:35 AM ET · Deal
Harrow, Inc. has finalized a big deal to buy TYRVAYA nasal spray for $30 million.
Good for HROW
Harrow completed its purchase of TYRVAYA rights outside Japan, adding a dry-eye treatment. Cash paid and future sales-based payments temper the cost, but added rights support a positive read.
Aug 21, 2026, 12:17 PM ET · Market
Iheezo from Harrow reduces discomfort during eye injections by over 50%.
Good for HROW
Harrow Inc. announced promising results from a clinical study of its IHEEZO product, showing a significant reduction in discomfort during eye injections. This breakthrough could improve patient compliance and position Harrow favorably in the ophthalmic market, attracting investor interest.
Aug 6, 2026, 2:06 PM ET · Market
Viatris enhances strategic direction through divestment, raises 2026 projections.
Good for HROW
Harrow's acquisition of Tyrvaya from Viatris may enhance its product portfolio and revenue potential.